Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Millrock Resources | JV Investment of $5 M into Gold Project

Today we share the value proposition of a Millrock Resources, a Premier Prospect Generator, that has a brownfields, district-scale land package located the prolific Tintina Gold Province of Alaska, surrounding 10 million ounces of gold in...
Maurice Jackson | June 9, 2020 |

Novamind Selected by Merck to Advance Research for Treatment-Resistant Depression

Novamind’s subsidiary, Cedar Clinical Research, to serve as a key clinical research site Independent validation of the expertise and capabilities of Novamind in managing clinical trials Adds to established track record conducting research a...
Featured Submission | March 18, 2021 |

Buzz on the Bullboards: Three newsmakers during TSX’s rebound

The TSX experienced a roller-coaster week, starting with notable losses but ending with a robust rebound, leading to significant gains. This positive shift has supported investor confidence, proving that it is important to stay updated with recent developments. Let&CloseC...
Jonathon Brown | August 1, 2024 |

NurExone Biologic announces important test results

By Brad Sorensen, CFA, Zacks Research. NurExone Biologic (TSXV:NRX; OTCQB:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ExoPTEN m...
Research | December 11, 2024 |

Gold Explorer Expands at the Perfect Time

(Image via Nexus Gold. Click image to enlarge) Nexus Gold Corp. ( TSX-V:NXS , OTC:NXXGF , Forum ) seems to have picked the perfect time to start heating up. A glance at the junior gold exploration company’s newsfeed will reveal t...
Omri Wallach | September 10, 2019 |

Miner Finding High-Grade Gold and Silver in Colombia Attracts Investment by Eric Sprott

Outcrop Gold is wholly focused on its Colombia properties that have a long history of high-grade production. Outcrop Gold's Colombia Projects Outcrop Gold Corp.'s (OCG:TSX.V; MRDDF:OTCPK; MRG1:FSE) coffers and profile received a boo...
Streetwise Reports | April 7, 2020 |

Interview: Newlox CEO Ryan Jackson on building a green gold producer with rapid growth trajectory

Newlox Gold Ventures Corp. ( CSE: LUX ) is an innovative junior gold production and green technology company targeting the USD 27 billion artisanal and small-scale mining industry. Newlox Gold has one gold production facility in production. It is exploiting a first-mover&Clo...
Mario Hose | October 13, 2020 |

Leading Edge Materials: Positioning for the EU’s critical minerals push

By David Yeoman, Crux Investor Leading Edge Materials has a portfolio of critical raw materials projects in the EU, including the Norra Kärr heavy rare earths project in Sweden, the Woxna graphite mine in Sweden, and an exploration program in Romania. ...
Research | October 30, 2024 |

Ovid Therapeutics Posts Positive Data from Phase 2 Seizure Reduction Trial

Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies. Shares of Ovid Therapeutics Inc. (OVID:NASDAQ) are tra...
Streetwise Reports | September 25, 2019 |

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results

Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint. This morning Marinus Pharmaceuticals Inc. (MRNS:NASDAQ) , a pharmaceutical firm dedicated to...
Streetwise Reports | September 27, 2019 |
1 2 3 4 5 6 7 8 9 10